Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Challenges in Mesenchymal Stromal Cell-based Therapies

Author(s): Maria Kavianpour, Lindolfo da Silva Meirelles and Naser Ahmadbeigi*

Volume 18, Issue 7, 2023

Published on: 18 October, 2022

Page: [937 - 946] Pages: 10

DOI: 10.2174/1574888X17666220831104747

Price: $65

Abstract

Over 50 years have passed since discovering mesenchymal stromal cells (MSCs). Initially, despite gaps in the knowledge of the identity of these cells, their therapeutic aspects were recognized. Consequently, MSCs became candidates for treating a wide range of diseases. However, the therapeutic effects of MSCs are not stable in the long term, and there are inconsistent data on their clinical efficacy. Even though more than 1000 MSC-based clinical trials have been registered, and the safety of MSCbased cell therapies has been proven, data on the clinical efficacy of MSCs have not been enough to warrant FDA approval for clinical treatment and marketing purposes. The available information on MSCs still contains some controversies, perhaps owing to little progress in understanding their in vivo identity. MSCs have been used for therapeutic purposes despite poor knowledge of their in vivo origin or functions. Hence, perhaps we need to go back to the basics of MSCs and spend more time understanding the biology of these cells. An improved understanding of MSCs' location and function within tissues may improve their therapeutic efficacy and, consequently, their establishment as a cell therapy product.

Keywords: Mesenchymal Stromal Cell, Challenges, Cell Therapy

« Previous Next »
Graphical Abstract

[1]
Fridenshteĭn AIa, Petrakova KV, Kuralesova AI, Frolova GI. Precursor cells for osteogenic and hemopoietic tissues. Analysis of heterotopic transplants of bone marrow. Tsitologiia 1968; 10(5): 557-67.
[PMID: 4885074]
[2]
Ai J, Ketabchi N, Verdi J, Gheibi N, Khadem Haghighian H, Kavianpour M. Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways. Cancer Cell Int 2019; 19(1): 329.
[http://dx.doi.org/10.1186/s12935-019-1038-0] [PMID: 31827403]
[3]
Cowper M, Frazier T, Wu X, et al. Human platelet lysate as a functional substitute for fetal bovine serum in the culture of human adipose derived stromal/stem cells. Cells 2019; 8(7): 724.
[http://dx.doi.org/10.3390/cells8070724] [PMID: 31311198]
[4]
Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2(2): 83-92.
[PMID: 4455512]
[5]
Caplan AI. Mesenchymal stem cells: Time to change the name! Stem Cells Transl Med 2017; 6(6): 1445-51.
[http://dx.doi.org/10.1002/sctm.17-0051] [PMID: 28452204]
[6]
Fitzsimmons REB, Mazurek MS, Soos A, Simmons CA. Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. Stem Cells Int 2018; 2018: 8031718.
[http://dx.doi.org/10.1155/2018/8031718] [PMID: 30210552]
[7]
Lindner U, Kramer J, Behrends J, et al. Aging and replicative senescence of human mesenchymal stromal cells is accompanied by increased loss of RS-cell-subpopulation. J Stem Cells Regen Med 2010; 6(2): 107.
[PMID: 24693121]
[8]
D’Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC. marrow-Isolated Adult Multilineage Inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117(14): 2971-81.
[http://dx.doi.org/10.1242/jcs.01103] [PMID: 15173316]
[9]
Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109(10): 1291-302.
[http://dx.doi.org/10.1172/JCI0215182] [PMID: 12021244]
[10]
Da Silva ML, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26(9): 2287-99.
[http://dx.doi.org/10.1634/stemcells.2007-1122] [PMID: 18566331]
[11]
Trivanović D,, Jauković A,, Popović B,. et al. Mesenchymal stem cells of different origin: Comparative evaluation of proliferative capacity, telomere length and pluripotency marker expression. Life Sci 2015; 141: 61-73.
[http://dx.doi.org/10.1016/j.lfs.2015.09.019 ] [PMID: 26408916]
[12]
Mastrolia I, Foppiani EM, Murgia A, et al. Challenges in clinical development of mesenchymal stromal/stem cells: Concise review. Stem Cells Transl Med 2019; 8(11): 1135-48.
[http://dx.doi.org/10.1002/sctm.19-0044] [PMID: 31313507]
[13]
Covas DT, Panepucci RA, Fontes AM, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008; 36(5): 642-54.
[http://dx.doi.org/10.1016/j.exphem.2007.12.015] [PMID: 18295964]
[14]
Alt E, Yan Y, Gehmert S, et al. Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. Biol Cell 2011; 103(4): 197-208.
[http://dx.doi.org/10.1042/BC20100117] [PMID: 21332447]
[15]
Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 2011; 20(1): 53-66.
[http://dx.doi.org/10.1089/scd.2010.0040] [PMID: 20528146]
[16]
Cappellesso FS, Puissant LB, Apoil PA, et al. Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells. J Clin Immunol 2010; 30(4): 607-19.
[http://dx.doi.org/10.1007/s10875-010-9415-4] [PMID: 20405178]
[17]
Lorenz K, Sicker M, Schmelzer E, et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp Dermatol 2008; 17(11): 925-32.
[http://dx.doi.org/10.1111/j.1600-0625.2008.00724.x] [PMID: 18557932]
[18]
De Souza LEB, Malta TM, Kashima HS, Covas DT. Mesenchymal stem cells and pericytes: To what extent are they related? Stem Cells Dev 2016; 25(24): 1843-52.
[http://dx.doi.org/10.1089/scd.2016.0109] [PMID: 27702398]
[19]
Feng J, Mantesso A, Sharpe PT. Perivascular cells as mesenchymal stem cells. Expert Opin Biol Ther 2010; 10(10): 1441-51.
[http://dx.doi.org/10.1517/14712598.2010.517191] [PMID: 20836622]
[20]
Meirelles LS, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119(11): 2204-13.
[http://dx.doi.org/10.1242/jcs.02932] [PMID: 16684817]
[21]
Gheisari Y, Ahmadbeigi N. Mesenchymal stem cells and endothelial cells: A common ancestor? Arch Iran Med 2016; 19(8): 584-7.
[PMID: 27544368]
[22]
Coste C, Neirinckx V, Sharma A, et al. Human bone marrow harbors cells with neural crest-associated characteristics like human adipose and dermis tissues. PLoS One 2017; 12(7): e0177962.
[http://dx.doi.org/10.1371/journal.pone.0177962] [PMID: 28683107]
[23]
Takashima Y, Era T, Nakao K, et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007; 129(7): 1377-88.
[http://dx.doi.org/10.1016/j.cell.2007.04.028] [PMID: 17604725]
[24]
Murray IR, Péault B. Q&A: Mesenchymal stem cells — Where do they come from and is it important? BMC Biol 2015; 13(1): 99.
[http://dx.doi.org/10.1186/s12915-015-0212-7] [PMID: 26596888]
[25]
Augello A, Kurth TB, De Bari C. Mesenchymal stem cells: A perspective from in vitro cultures to in vivo migration and niches. Eur Cell Mater 2010; 20: 121-33.
[http://dx.doi.org/10.22203/eCM.v020a11] [PMID: 21249629]
[26]
Naji A, Favier B, Deschaseaux F, Rouas-Freiss N, Eitoku M, Suganuma N. Mesenchymal stem/stromal cell function in modulating cell death. Stem Cell Res Ther 2019; 10(1): 56.
[http://dx.doi.org/10.1186/s13287-019-1158-4] [PMID: 30760307]
[27]
Pontikoglou C, Deschaseaux F, Sensebé L, Papadaki HA. Bone marrow mesenchymal stem cells: Biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev 2011; 7(3): 569-89.
[http://dx.doi.org/10.1007/s12015-011-9228-8] [PMID: 21249477]
[28]
Gómez GMV, Lovell BR, Fernández AF, Lara-Pezzi E. The vascular stem cell niche. J Cardiovasc Transl Res 2012; 5(5): 618-30.
[http://dx.doi.org/10.1007/s12265-012-9371-x] [PMID: 22644724]
[29]
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006; 8(4): 315-7.
[http://dx.doi.org/10.1080/14653240600855905] [PMID: 16923606]
[30]
Chen S, Fan J, Zhang M, et al. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat Commun 2019; 10(1): 150.
[http://dx.doi.org/10.1038/s41467-018-08123-8] [PMID: 30635578]
[31]
Moazen B, Zarrinhaghighi A, Nejatollahi F. Selection and evaluation of specific single chain antibodies against CD90, a marker for mesenchymal and cancer stem cells. Rep Biochem Mol Biol 2018; 7(1): 45-51.
[PMID: 30324117]
[32]
Kisselbach L, Merges M, Bossie A, Boyd A. CD90 expression on human primary cells and elimination of contaminating fibroblasts from cell cultures. Cytotechnology 2009; 59(1): 31-44.
[http://dx.doi.org/10.1007/s10616-009-9190-3] [PMID: 19296231]
[33]
Sauzay C, Voutetakis K, Chatziioannou A, Chevet E, Avril T. CD90/Thy-1, A cancer-associated cell surface signaling molecule. Front Cell Dev Biol 2019; 7: 66.
[http://dx.doi.org/10.3389/fcell.2019.00066] [PMID: 31080802]
[34]
Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14(7): 1931-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-4478] [PMID: 18381930]
[35]
Muñiz C,, Teodosio C,, Mayado A,. et al. Ex vivo identification and characterization of a population of CD13 high CD105+ CD45− mesenchymal stem cells in human bone marrow. Stem Cell Res Ther 2015; 6(1): 169.
[http://dx.doi.org/ 10.1186/s13287-015-0152-8] [PMID: 26347461]
[36]
Lv FJ, Tuan RS, Cheung KMC, Leung VYL. Concise review: The surface markers and identity of human mesenchymal stem cells. Stem Cells 2014; 32(6): 1408-19.
[http://dx.doi.org/10.1002/stem.1681] [PMID: 24578244]
[37]
Kozlowska U, Krawczenko A, Futoma K, et al. Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues. World J Stem Cells 2019; 11(6): 347-74.
[http://dx.doi.org/10.4252/wjsc.v11.i6.347] [PMID: 31293717]
[38]
Braun J, Kurtz A, Barutcu N, Bodo J, Thiel A, Dong J. Concerted regulation of CD34 and CD105 accompanies mesenchymal stromal cell derivation from human adventitial stromal cell. Stem Cells Dev 2013; 22(5): 815-27.
[http://dx.doi.org/10.1089/scd.2012.0263] [PMID: 23072708]
[39]
Rombouts WJC, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17(1): 160-70.
[http://dx.doi.org/10.1038/sj.leu.2402763] [PMID: 12529674]
[40]
Ahmadbeigi N, Seyedjafari E, Gheisari Y, Atashi A, Omidkhoda A, Soleimani M. Surface expression of CXCR4 in unrestricted somatic stem cells and its regulation by growth factors. Cell Biol Int 2010; 34(7): 687-92.
[http://dx.doi.org/10.1042/CBI20090415] [PMID: 20196768]
[41]
Gheisari Y, Azadmanesh K, Ahmadbeigi N, et al. Genetic modification of mesenchymal stem cells to overexpress CXCR4 and CXCR7 does not improve the homing and therapeutic potentials of these cells in experimental acute kidney injury. Stem Cells Dev 2012; 21(16): 2969-80.
[http://dx.doi.org/10.1089/scd.2011.0588] [PMID: 22563951]
[42]
Pierini M, Dozza B, Lucarelli E, et al. Efficient isolation and enrichment of mesenchymal stem cells from bone marrow. Cytotherapy 2012; 14(6): 686-93.
[http://dx.doi.org/10.3109/14653249.2012.677821] [PMID: 22574721]
[43]
Insausti CL, Blanquer Blanquer M, Meseguer Olmo L, et al. Isolation and characterization of mesenchymal stem cells from the fat layer on the density gradient separated bone marrow. Stem Cells Dev 2012; 21(2): 260-72.
[http://dx.doi.org/10.1089/scd.2010.0572] [PMID: 21504358]
[44]
Horn P, Bork S, Diehlmann A, et al. Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis. Cytotherapy 2008; 10(7): 676-85.
[http://dx.doi.org/10.1080/14653240802398845] [PMID: 18985474]
[45]
Horn P, Bork S, Wagner W. Standardized isolation of human mesenchymal stromal cells with red blood cell lysis. Methods Mol Biol 2011; 698: 23-35.
[http://dx.doi.org/10.1007/978-1-60761-999-4_3] [PMID: 21431508]
[46]
Pösel C, Möller K, Fröhlich W, Schulz I, Boltze J, Wagner DC. Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS One 2012; 7(12): e50293.
[http://dx.doi.org/10.1371/journal.pone.0050293] [PMID: 23236366]
[47]
Ahmadbeigi N, Soleimani M, Babaeijandaghi F, et al. The aggregate nature of human mesenchymal stromal cells in native bone marrow. Cytotherapy 2012; 14(8): 917-24.
[http://dx.doi.org/10.3109/14653249.2012.689426] [PMID: 22687188]
[48]
Jin JD, Wang HX, Xiao FJ, et al. A novel rich source of human mesenchymal stem cells from the debris of bone marrow samples. Biochem Biophys Res Commun 2008; 376(1): 191-5.
[http://dx.doi.org/10.1016/j.bbrc.2008.08.131] [PMID: 18774774]
[49]
Blazsek I, Misset JL, Comisso M, Mathé G. Hematon: A multicellular functional unit in primary hematopoiesis. Biomed Pharmacother 1988; 42(10): 661-8.
[PMID: 3266080]
[50]
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov 2020; 19(3): 200-18.
[http://dx.doi.org/10.1038/s41573-019-0052-1] [PMID: 31907401]
[51]
Salmikangas P, Kinsella N, Chamberlain P. Chimeric Antigen Receptor T-cells (CAR T-cells) for cancer immunotherapy – Moving target for industry? Pharm Res 2018; 35(8): 152.
[http://dx.doi.org/10.1007/s11095-018-2436-z] [PMID: 29855723]
[52]
Galipeau J. The mesenchymal stromal cells dilemma—Does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013; 15(1): 2-8.
[http://dx.doi.org/10.1016/j.jcyt.2012.10.002] [PMID: 23260081]
[53]
Jiang W, Ma A, Wang T, et al. Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: A time-series study. Pflugers Arch 2006; 453(1): 43-52.
[http://dx.doi.org/10.1007/s00424-006-0117-y] [PMID: 16915405]
[54]
Duan X, Lu L, Wang Y, et al. The long-term fate of mesenchymal stem cells labeled with magnetic resonance imaging-visible polymersomes in cerebral ischemia. Int J Nanomedicine 2017; 12: 6705-19.
[http://dx.doi.org/10.2147/IJN.S146742] [PMID: 28932115]
[55]
Morigi M, Introna M, Imberti B, et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008; 26(8): 2075-82.
[http://dx.doi.org/10.1634/stemcells.2007-0795] [PMID: 18499895]
[56]
Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15(7): 1794-804.
[http://dx.doi.org/10.1097/01.ASN.0000128974.07460.34] [PMID: 15213267]
[57]
Von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012; 30(7): 1575-8.
[http://dx.doi.org/10.1002/stem.1118] [PMID: 22553154]
[58]
Mancuso P, Raman S, Glynn A, Barry F, Murphy JM. Mesenchymal stem cell therapy for osteoarthritis: The critical role of the cell secretome. Front Bioeng Biotechnol 2019; 7: 9.
[http://dx.doi.org/10.3389/fbioe.2019.00009] [PMID: 30761298]
[59]
Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 2016; 7(1): 125.
[http://dx.doi.org/10.1186/s13287-016-0363-7] [PMID: 27581859]
[60]
Crippa S, Bernardo ME. Mesenchymal stromal cells: Role in the BM niche and in the support of hematopoietic stem cell transplantation. HemaSphere 2018; 2(6): e151.
[http://dx.doi.org/10.1097/HS9.0000000000000151] [PMID: 31723790]
[61]
Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009; 11(5): 503-15.
[http://dx.doi.org/10.1080/14653240903193806] [PMID: 19728189]
[62]
Noort WA, Kruisselbrink AB, In’t Anker PS, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood–derived CD34+ cells in NOD/SCID mice. Exp Hematol 2002; 30(8): 870-8.
[http://dx.doi.org/10.1016/S0301-472X(02)00820-2] [PMID: 12160838]
[63]
Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 2008; 22(3): 593-9.
[http://dx.doi.org/10.1038/sj.leu.2405090] [PMID: 18185520]
[64]
Fan XL, Zhang Y, Li X, Fu QL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci 2020; 77(14): 2771-94.
[http://dx.doi.org/10.1007/s00018-020-03454-6] [PMID: 31965214]
[65]
Regmi S, Pathak S, Kim JO, Yong CS, Jeong JH. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives. Eur J Cell Biol 2019; 98(5-8): 151041.
[http://dx.doi.org/10.1016/j.ejcb.2019.04.002] [PMID: 31023504]
[66]
Drela K, Stanaszek L, Nowakowski A, Kuczynska Z, Lukomska B. Experimental strategies of mesenchymal stem cell propagation: Adverse events and potential risk of functional changes. Stem Cells Int 2019; 2019: 7012692.
[http://dx.doi.org/10.1155/2019/7012692] [PMID: 30956673]
[67]
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995; 16(4): 557-64.
[PMID: 8528172]
[68]
Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012; 5(1): 19.
[http://dx.doi.org/10.1186/1756-8722-5-19] [PMID: 22546280]
[69]
Saeedi P, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. Stem Cell Investig 2019; 6: 34.
[http://dx.doi.org/10.21037/sci.2019.08.11] [PMID: 31620481]
[70]
Kavianpour M, Saleh M, Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: Focus on cytokine storm. Stem Cell Res Ther 2020; 11(1): 404.
[http://dx.doi.org/10.1186/s13287-020-01849-7] [PMID: 32948252]
[71]
Couto PS, Shatirishvili G, Bersenev A, Verter F. First decade of clinical trials and published studies with mesenchymal stromal cells from umbilical cord tissue. Regen Med 2019; 14(4): 309-19.
[http://dx.doi.org/10.2217/rme-2018-0171] [PMID: 31070115]
[72]
Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: An FDA perspective. Cell Stem Cell 2014; 14(2): 141-5.
[http://dx.doi.org/10.1016/j.stem.2014.01.013] [PMID: 24506881]
[73]
Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplant 2016; 25(5): 829-48.
[http://dx.doi.org/10.3727/096368915X689622] [PMID: 26423725]
[74]
Galipeau J, Sensébé L. Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. Cell Stem Cell 2018; 22(6): 824-33.
[http://dx.doi.org/10.1016/j.stem.2018.05.004] [PMID: 29859173]
[75]
Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 2018; 14(8): 493-507.
[http://dx.doi.org/10.1038/s41581-018-0023-5] [PMID: 29895977]
[76]
Syková E,, Homola A,, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006; 15(8-9): 675-87.
[http://dx.doi.org/10.3727/000000006783464381] [PMID: 17269439]
[77]
Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 2012; 114(7): 935-9.
[http://dx.doi.org/10.1016/j.clineuro.2012.02.003] [PMID: 22464434]
[78]
Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2017; 16(5): 360-8.
[http://dx.doi.org/10.1016/S1474-4422(17)30046-7] [PMID: 28320635]
[79]
Staff NP, Madigan NN, Morris J, et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology 2016; 87(21): 2230-4.
[http://dx.doi.org/10.1212/WNL.0000000000003359] [PMID: 27784774]
[80]
Yau TM, Pagani FD, Mancini DM, et al. Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure. JAMA 2019; 321(12): 1176-86.
[http://dx.doi.org/10.1001/jama.2019.2341] [PMID: 30912838]
[81]
Hu X, Majeed N, Zhang Y, Hu X. Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: Preliminary results. Med Sci Monit 2013; 19: 852-7.
[http://dx.doi.org/10.12659/MSM.889525] [PMID: 24121994]
[82]
Thakkar UG, Trivedi HL, Vanikar AV, Dave SD. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow–derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy 2015; 17(7): 940-7.
[http://dx.doi.org/10.1016/j.jcyt.2015.03.608] [PMID: 25869301]
[83]
Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015; 64(2): 587-92.
[http://dx.doi.org/10.2337/db14-0656] [PMID: 25204974]
[84]
Mohyeddin BM, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4(1): 50-7.
[PMID: 17652844]
[85]
Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study. Respir Res 2014; 15(1): 39.
[http://dx.doi.org/10.1186/1465-9921-15-39] [PMID: 24708472]
[86]
Ahmadbeigi N, Soleimani M, Gheisari Y, et al. Dormant phase and multinuclear cells: Two key phenomena in early culture of murine bone marrow mesenchymal stem cells. Stem Cells Dev 2011; 20(8): 1337-47.
[http://dx.doi.org/10.1089/scd.2010.0266] [PMID: 21083430]
[87]
Moein S, Adibi R, Da Silva Meirelles L, Nardi NB, Gheisari Y. Cancer regeneration: Polyploid cells are the key drivers of tumor progression. Biochim Biophys Acta Rev Cancer 2020; 1874(2): 188408.
[http://dx.doi.org/10.1016/j.bbcan.2020.188408] [PMID: 32827584]
[88]
Sivasubramaniyan K, Harichandan A, Schumann S, et al. Prospective isolation of mesenchymal stem cells from human bone marrow using novel antibodies directed against Sushi domain containing 2. Stem Cells Dev 2013; 22(13): 1944-54.
[http://dx.doi.org/10.1089/scd.2012.0584] [PMID: 23406305]
[89]
Lin G, Liu G, Banie L, et al. Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev 2011; 20(10): 1747-52.
[http://dx.doi.org/10.1089/scd.2010.0564] [PMID: 21208041]
[90]
Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007; 1106(1): 262-71.
[http://dx.doi.org/10.1196/annals.1392.000] [PMID: 17395729]
[91]
Battula VL, Treml S, Abele H, Bühring HJ. Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. Differentiation 2008; 76(4): 326-36.
[http://dx.doi.org/10.1111/j.1432-0436.2007.00225.x] [PMID: 17924962]
[92]
Watson JT, Foo T, Wu J, et al. CD271 as a marker for mesenchymal stem cells in bone marrow versus umbilical cord blood. Cells Tissues Organs 2013; 197(6): 496-504.
[http://dx.doi.org/10.1159/000348794] [PMID: 23689142]
[93]
Calabrese G, Giuffrida R, Lo Furno D, et al. Potential effect of CD271 on human mesenchymal stromal cell proliferation and differentiation. Int J Mol Sci 2015; 16(12): 15609-24.
[http://dx.doi.org/10.3390/ijms160715609] [PMID: 26184166]
[94]
Alexander D, Schäfer F,, Olbrich M, et al. MSCA-1/TNAP selection of human jaw periosteal cells improves their mineralization capacity. Cell Physiol Biochem 2010; 26(6): 1073-80.
[http://dx.doi.org/10.1159/000323985] [PMID: 21220938]
[95]
De Ugarte DA, Alfonso Z, Zuk PA, et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett 2003; 89(2-3): 267-70.
[http://dx.doi.org/10.1016/S0165-2478(03)00108-1] [PMID: 14556988]
[96]
Abdal DA, Lee SB, Kim K, et al. Production of mesenchymal stem cells through stem cell reprogramming. Int J Mol Sci 2019; 20(8): 1922.
[http://dx.doi.org/10.3390/ijms20081922] [PMID: 31003536]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy